Received Jun 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (PRIORIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 342RC | — |
no sero conversion rate on a patient; This non-serious case was reported by a physician via call center representative and described the occurrence of therapy non-responder in a 33-year-old female patient who received MMR (Priorix) (batch number 342RC, expiry date 01-MAY-2025) for prophylaxis. This case was associated with a product complaint. On 05-FEB-2025, the patient received Priorix. On an unknown date, an unknown time after receiving Priorix, the patient experienced therapy non-responder (Verbatim: no sero conversion rate on a patient). The outcome of the therapy non-responder was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 27-MAY-2025 The physician wanted to know what was the likely hood of no sero conversion rate on a patient. The physician was not sure if the vaccine was administer at the same zip code. No further information was obtained in this call. Suspect product was now expired. Consented to follow up.